Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from PureTech Health ( (GB:PRTC) ) is now available.
PureTech Health announced that 25% of restricted share units granted to Robert Lyne, Chief Portfolio Officer, vested on February 1, 2025, with shares issued on July 1, 2025. The transaction involved the sale and subsequent purchase of 33,561 shares by Lyne, reflecting strategic financial management and potentially impacting shareholder dynamics.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall stock score reflects a strong financial position and positive corporate developments, tempered by ongoing profitability challenges and bearish technical indicators. The company’s strategic achievements and undervalued P/E ratio are positive, but operational risks and funding concerns for trials remain significant.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine aimed at treating devastating diseases. The company has a diverse portfolio of 29 therapeutics and therapeutic candidates, including three approved by the U.S. FDA, developed through its robust R&D team and network of experts.
Average Trading Volume: 554,413
Technical Sentiment Signal: Sell
Current Market Cap: £304.6M
Find detailed analytics on PRTC stock on TipRanks’ Stock Analysis page.